CLINICAL TRIAL AGREEMENT PROTOCOL NUMBER: TQ-BA-2024-1 (NCT06207370) PROTOCOL TITLE: “Double-blind Placebo-controlled Study to Assess the Safety and Efficacy of Oral Tafenoquine plus Standard of Care versus Placebo plus Standard of Care in Patients...Clinical Trial Agreement • September 19th, 2024 • 60 Degrees Pharmaceuticals, Inc. • Pharmaceutical preparations
This Clinical Trial Agreement (this “Agreement”) is effective as of the last date of signature (the “Effective Date”) and sets forth certain agreements by and between 60 DEGREES PHARMACEUTICALS, INC , having its principal place of business at 1025 Connecticut Ave NW, Washington DC, 20036 (“Sponsor”), and Rhode Island Hospital with a principal place of business at 593 Eddy Street, Providence RI 02903 (hereinafter referred to as “Institution”), The persons executing this Agreement hereby represent that they are authorized to do so for and on behalf of the above-named companies and organizations.
